Financial reports
10-Q
2018 Q1
Quarterly report
15 May 18
10-K
2017 FY
Annual report
5 Mar 18
10-Q
2017 Q3
Quarterly report
8 Nov 17
10-Q
2017 Q2
Quarterly report
9 Aug 17
10-Q
2017 Q1
Quarterly report
10 May 17
10-K
2016 FY
Annual report
16 Mar 17
10-Q
2016 Q3
Quarterly report
7 Nov 16
10-Q
2016 Q2
Quarterly report
9 Aug 16
10-Q
2016 Q1
Quarterly report
10 May 16
Current reports
8-K
Anthera Pharmaceuticals Announces SEC Deregistration
9 Jul 18
8-K
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request
27 Jun 18
8-K
Departure of Directors or Certain Officers
18 Jun 18
8-K
Other Events
30 May 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 May 18
8-K
Cost Associated with Exit or Disposal Activities
16 Apr 18
8-K
Anthera Pharmaceuticals Reports Top Line Data from
12 Mar 18
8-K
Anthera Pharmaceuticals Provides Business Update and Reports
5 Mar 18
8-K
Anthera Receives Positive Nasdaq Listing Determination
25 Jan 18
8-K
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
9 Jan 18
Registration and prospectus
15-12B
Securities registration termination
30 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
RW
Registration withdrawal request
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
Proxies
DEF 14A
Definitive proxy
4 Dec 17
PRE 14A
Preliminary proxy
20 Nov 17
DEF 14A
Definitive proxy
16 Mar 17
DEFA14A
Additional proxy soliciting materials
16 Mar 17
PRE 14A
Preliminary proxy
24 Feb 17
DEFA14A
Additional proxy soliciting materials
17 Mar 16
DEF 14A
Definitive proxy
15 Mar 16
DEFA14A
Additional proxy soliciting materials
15 Mar 16
DEF 14A
Definitive proxy
9 Apr 15
DEFA14A
Additional proxy soliciting materials
9 Apr 15
Other
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Mar 18
UPLOAD
Letter from SEC
1 Dec 17
CORRESP
Correspondence with SEC
30 Nov 17
Ownership
3
Mark Drew McManigle
12 Sep 18
SC 13G/A
Anthera Pharmaceuticals Inc
22 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
5 Feb 18
SC 13G
Anthera Pharmaceuticals Inc
18 Jan 18
4
CHRISTOPHER S HENNEY
9 Jan 18
4
PAUL F TRUEX
9 Jan 18
4
Brent Furse
9 Jan 18
4
MAY LIU
9 Jan 18